Last reviewed 2026-04-20 · How we verify

TAFAMIDIS MEGLUMINE

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Discontinued the study drug because of an adverse event

Drug interactions

• BCRP substrates (e.g., methotrexate, rosuvastatin, imatinib)

Key clinical trials

• A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
• Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
• A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions (PHASE1)
• Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
• A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (PHASE4)
• Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study
• Amyloidosis TTR Flow Reserve Evaluation (NA)
• A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TAFAMIDIS MEGLUMINE CI brief — competitive landscape report
• TAFAMIDIS MEGLUMINE updates RSS · CI watch RSS